Pseudoprogression after glioma therapy: A comprehensive review

Expert Review of Neurotherapeutics

Volumn 13, Issue 4, 2013, Pages 389-403

  Kruser, Tim J ^a,b   Mehta, Minesh P ^c   Robins, H Ian ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b Radiation Oncology Consultants Ltd   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

glioblastoma; pseudoprogression; radiation necrosis; temozolomide

Indexed keywords

CARMUSTINE; FERUMOXYTOL; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; HYDROXYUREA; KI 67 ANTIGEN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NITROSOUREA; PROTEIN P53; TEMOZOLOMIDE; TRACER;

ADJUVANT CHEMORADIOTHERAPY; BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL DECISION MAKING; CLINICAL FEATURE; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; GENE OVEREXPRESSION; GLIOBLASTOMA; GLIOMA; HUMAN; INCIDENCE; LONG TERM SURVIVAL; METHYLATION; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATIENT COMPLIANCE; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PROMOTER REGION; PSEUDOPROGRESSION; RADIATION DOSE; RADIATION NECROSIS; RADIATION RESPONSE; RADIOSENSITIZATION; REVIEW; SENSITIVITY AND SPECIFICITY; SUSCEPTIBILITY WEIGHTED IMAGING; TUMOR GROWTH; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE PROGRESSION; GLIOMA; HUMANS; NEOPLASM RECURRENCE, LOCAL; RADIATION INJURIES; RADIOTHERAPY;

EID: 84875884279     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.13.7     Document Type: Review

References (93)

1. Walker MD, Alexander E Jr, Hunt WE et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J. Neurosurg. 49(3), 333-343 (1978).
2. Kristiansen K, Hagen S, Kollevold T et al. Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 47(4), 649-652 (1981).
3. Walker MD, Green SB, Byar DP et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N. Engl. J. Med. 303(23), 1323-1329 (1980).
4. Nelson DF, Diener-West M, Horton J, Chang CH, Schoenfeld D, Nelson JS. Combined modality approach to treatment of malignant gliomas - re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group. NCI Monogr. 6, 279-284 (1988).
5. Souhami L, Seiferheld W, Brachman D et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int. J. Radiat. Oncol. Biol. Phys. 60(3), 853-860 (2004).
6. Selker RG, Shapiro WR, Burger P et al.; Brain Tumor Cooperative Group. The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery 51(2), 355; discussion 355 (2002).
7. Prados MD, Wara WM, Sneed PK et al. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 49(1), 71-77 (2001).
8. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for Phase II studies of supratentorial malignant glioma. J. Clin. Oncol. 8(7), 1277-1280 (1990).
9. Nieder C, Adam M, Molls M, Grosu AL. Therapeutic options for recurrent high-grade glioma in adult patients: recent advances. Crit. Rev. Oncol. Hematol. 60(3), 193 (2006).
10. Stupp R, Mason WP, van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352(10), 987-996 (2005).
11. Peca C, Pacelli R, Elefante A et al. Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis? Clin. Neurol. Neurosurg. , 331-334 (2009).
12. Cohen MH, Shen YL, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 14(11), 1138 (2009).
13. Robins HI, Lassman AB, Khuntia D. Therapeutic advances in malignant glioma: current status and future prospects. Neuroimaging Clin. N. Am. 19(4), 647-656 (2009).
14. Levin VA, Bidaut L, Hou P et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int. J. Radiat. Oncol. Biol. Phys. 79(5), 1495 (2011).
15. Wen PY, Macdonald DR, Reardon DA et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J. Clin. Oncol. 28(11), 1963-1972 (2010).
16. Grossman SA, Ye X, Piantadosi S et al.; NABTT CNS Consortium. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin. Cancer Res. 16(8), 2443-2449 (2010).
17. Sanghera P, Rampling R, Haylock B et al. The concepts, diagnosis and management of early imaging changes after therapy for glioblastomas. Clin. Oncol. (R. Coll. Radiol.) 24(3), 216-227 (2012).
18. Rhee DJ, Kong DS, Kim WS et al. Efficacy of temozolomide as adjuvant chemotherapy after postsurgical radiotherapy alone for glioblastomas. Clin. Neurol. Neurosurg.
19. Combs SE, Wagner J, Bischof M et al. Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients. Int. J. Radiat. Oncol. Biol. Phys. , 987-992 (2008).
20. Malkoun N, Chargari C, Forest F et al. Prolonged temozolomide for treatment of glioblastoma: preliminary clinical results and prognostic value of p53 overexpression. J. Neurooncol. 106(1), 127-133 (2012).
21. Hoffman WF, Levin VA, Wilson CB. Evaluation of malignant glioma patients during the postirradiation period. J. Neurosurg. 50(5), 624-628 (1979).
22. Watne K, Hager B, Heier M, Hirschberg H. Reversible oedema and necrosis after irradiation of the brain. Diagnostic procedures and clinical manifestations. Acta Oncol. 29(7), 891-895 (1990).
23. Boldrey E, Sheline G. Delayed transitory clinical manifestations after radiation treatment of intracranial tumors. Acta Radiol. Ther. Phys. Biol. 5, 5-10 (1966).
24. Graeb DA, Steinbok P, Robertson WD. Transient early computed tomographic changes mimicking tumor progression after brain tumor irradiation. Radiology 144(4), 817 (1982).
25. Griebel M, Friedman HS, Halperin EC et al. Reversible neurotoxicity following hyperfractionated radiation therapy of brain stem glioma. Med. Pediatr. Oncol. , 182-186 (1991).
26. Rider WD. Radiation damage to the brain - a new syndrome. J. Can. Assoc. Radiol. , 67-69 (1963).
27. de Wit MC, de Bruin HG, Eijkenboom W, Sillevis Smitt PA, van den Bent MJ. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 63(3), 535-537 (2004).
28. Chamberlain MC, Glantz MJ, Chalmers L, Van Horn A, Sloan AE. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J. Neurooncol. 82(1), 81-83 (2007).
29. Chakravarti A, Erkkinen MG, Nestler U et al. Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin. Cancer Res. , 4738-4746 (2006).
30. Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 113(2), 405-410 (2008).
31. Brandes AA, Tosoni A, Spagnolli F et al. Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. Neuro-oncology 10(3), 361-367 (2008).
32. Chaskis C, Neyns B, Michotte A, De Ridder M, Everaert H. Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations. Surg. Neurol. 72(4), 428 (2009).
33. Clarke JL, Iwamoto FM, Sul J et al. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J. Clin. Oncol. , 3861-3867 (2009).
34. Fabi A, Russillo M, Metro G, Vidiri A, Di Giovanni S, Cognetti F. Pseudoprogression and MGMT status in glioblastoma patients: implications in clinical practice. Anticancer Res. 29(7), 2607-2610 (2009).
35. Gerstner ER, McNamara MB, Norden AD, Lafrankie D, Wen PY. Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. J. Neurooncol. 94(1), 97-101 (2009).
36. Gunjur A, Lau E, Taouk Y, Ryan G. Early post-treatment pseudo-progression amongst glioblastoma multiforme patients treated with radiotherapy and temozolomide: a retrospective analysis. J. Med. Imaging Radiat. Oncol. 55(6), 603-610 (2011).
37. Kang HC, Kim CY, Han JH et al. Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53. J. Neurooncol. 102(1), 157-162 (2011).
38. Kong DS, Kim ST, Kim EH et al. Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas: the role of assessing relative cerebral blood flow volume and oxygen-6-methylguanine- DNA methyltransferase promoter methylation status. AJNR. Am. J. Neuroradiol. 32(2), 382-387 (2011).
39. Park CK, Kim J, Yim SY et al. Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients. Neuro-oncology 13(2), 195-202 (2011).
40. Pouleau HB, Sadeghi N, Balériaux D, Mélot C, De Witte O, Lefranc F. High levels of cellular proliferation predict pseudoprogression in glioblastoma patients. Int. J. Oncol. 40(4), 923-928 (2012).
41. Roldán GB, Scott JN, McIntyre JB et al. Population-based study of pseudoprogression after chemoradiotherapy in GBM. Can. J. Neurol. Sci. 36(5), 617-622 (2009).
42. Sanghera P, Perry J, Sahgal A et al. Pseudoprogression following chemoradiotherapy for glioblastoma multiforme. Can. J. Neurol. Sci. 37(1), 36-42 (2010).
43. Tsien C, Galbán CJ, Chenevert TL et al. Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. J. Clin. Oncol. 28(13), 2293-2299 (2010).
44. Yaman E, Buyukberber S, Benekli M et al. Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide. Clin. Neurol. Neurosurg. , 662-667 (2010). , 662-667 (2010).
45. Young RJ, Gupta A, Shah AD et al. Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma. Neurology 76(22), 1918-1924 (2011).
46. Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J. Clin. Oncol. , 2192-2197 (2008).
47. Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352(10), 997-1003 (2005).
48. Mullins ME, Barest GD, Schaefer PW, Hochberg FH, Gonzalez RG, Lev MH. Radiation necrosis versus glioma recurrence: conventional MR imaging clues to diagnosis. AJNR. Am. J. Neuroradiol. , 1967-1972 (2005).
49. Hein PA, Eskey CJ, Dunn JF, Hug EB. Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury. AJNR. Am. J. Neuroradiol. 25(2), 201-209 (2004).
50. Asao C, Korogi Y, Kitajima M et al. Diffusion-weighted imaging of radiationinduced brain injury for differentiation from tumor recurrence. AJNR. Am. J. Neuroradiol. 26(6), 1455-1460 (2005).
51. Tung GA, Evangelista P, Rogg JM, Duncan JA 3rd. Diffusion-weighted MR imaging of rim-enhancing brain masses: is markedly decreased water diffusion specific for brain abscess? AJR. Am. J. Roentgenol. , 709-712 (2001).
52. Al Sayyari A, Buckley R, McHenery C, Pannek K, Coulthard A, Rose S. Distinguishing recurrent primary brain tumor from radiation injury: a preliminary study using a susceptibility-weighted MR imaging-guided apparent diffusion coefficient analysis strategy. AJNR. Am. J. Neuroradiol. 31(6), 1049-1054 (2010).
53. Hu LS, Baxter LC, Smith KA et al. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR. Am. J. Neuroradiol. 30(3), 552-558 (2009).
54. Gahramanov S, Raslan AM, Muldoon LL et al. Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibilityweighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study. Int. J. Radiat. Oncol. Biol. Phys. 79(2), 514-523 (2011).
55. Hu X, Wong KK, Young GS, Guo L, Wong ST. Support vector machine multiparametric MRI identification of pseudoprogression from tumor recurrence in patients with resected glioblastoma. J. Magn. Reson. Imaging 33(2), 296-305 (2011).
56. Narang J, Jain R, Arbab AS et al. Differentiating treatment-induced necrosis from recurrent/progressive brain tumor using nonmodel-based semiquantitative indices derived from dynamic contrast-enhanced T1-weighted MR perfusion. Neuro-oncology, 1037-1046 (2011).
57. Fatterpekar GM, Galheigo D, Narayana A, Johnson G, Knopp E. Treatment-related change versus tumor recurrence in high-grade gliomas: a diagnostic conundrum - use of dynamic susceptibility contrast-enhanced (DSC) perfusion MRI. AJR. Am. J. Roentgenol. 198(1), 19-26 (2012).
58. Kim YH, Oh SW, Lim YJ et al. Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI. Clin. Neurol. Neurosurg. 112(9), 758-765 (2010).
59. Gahramanov S, Muldoon LL, Varallyay CG et al. Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibilityweighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival. Radiology, 842-852 (2012).
60. Graber JJ, Young RJ, Gupta A et al. Magnetic resonance (MR) perfusion imaging to differentiate early progression from pseudoprogression following chemoradiotherapy for glioblastoma (GBM). J. Clin. Oncol. 29, Abstract 2009 (2011).
61. Gahramanov S, Muldoon LL, Li X, Neuwelt EA. Improved perfusion MR imaging assessment of intracerebral tumor blood volume and antiangiogenic therapy efficacy in a rat model with ferumoxytol. Radiology 261(3), 796-804 (2011).
62. Galbán CJ, Chenevert TL, Meyer CR et al. The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat. Med. 15(5), 572-576 (2009).
63. Schlemmer HP, Bachert P, Herfarth KK, Zuna I, Debus J, van Kaick G. Proton MR spectroscopic evaluation of suspicious brain lesions after stereotactic radiotherapy. AJNR. Am. J. Neuroradiol. 22(7), 1324 (2001).
64. Rock JP, Hearshen D, Scarpace L et al. Correlations between magnetic resonance spectroscopy and image-guided histopathology, with special attention to radiation necrosis. Neurosurgery 51(4), 912-919; discussion 919 (2002).
65. Rock JP, Scarpace L, Hearshen D et al. Associations among magnetic resonance spectroscopy, apparent diffusion coefficients, and image-guided histopathology with special attention to radiation necrosis. Neurosurgery 54(5), 1111-1117; discussion
66. Weybright P, Sundgren PC, Maly P et al. Differentiation between brain tumor recurrence and radiation injury using MR spectroscopy. AJR. Am. J. Roentgenol. , 1471-1476 (2005).
67. Zeng QS, Li CF, Zhang K, Liu H, Kang XS, Zhen JH. Multivoxel 3D proton MR spectroscopy in the distinction of recurrent glioma from radiation injury. J. Neurooncol. , 63-69 (2007).
68. Bobek-Billewicz B, Stasik-Pres G, Majchrzak H, Zarudzki L. Differentiation between brain tumor recurrence and radiation injury using perfusion, diffusion- weighted imaging and MR spectroscopy. Folia Neuropathol. 48(2), 92 (2010).
69. Zeng QS, Li CF, Liu H, Zhen JH, Feng DC. Distinction between recurrent glioma and radiation injury using magnetic resonance spectroscopy in combination with diffusion-weighted imaging. Int. J. Radiat. Oncol. Biol. Phys. 68(1), 151-158 (2007).
70. Matsusue E, Fink JR, Rockhill JK, Ogawa T, Maravilla KR. Distinction between glioma progression and post-radiation change by combined physiologic MR imaging. Neuroradiology 52(4), 297-306 (2010).
71. Ricci PE, Karis JP, Heiserman JE, Fram EK, Bice AN, Drayer BP. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? AJNR. Am. J. Neuroradiol. , 407-413 (1998).
72. Santra A, Kumar R, Sharma P et al. F-18 FDG PET-CT in patients with recurrent glioma: comparison with contrast enhanced MRI. Eur. J. Radiol. 81(3), 513 (2012).
73. Chen W. Clinical applications of PET in brain tumors. J. Nucl. Med. 48(9), 1481 (2007).
74. Chen W, Cloughesy T, Kamdar N et al. Imaging proliferation in brain tumors with F-FLT PET: comparison with 18F-FDG. J. Nucl. Med. 46(6), 945-952 (2005).
75. Wardak M, Schiepers C, Dahlbom M et al. Discriminant analysis of 18F-fluorothymidine kinetic parameters to predict survival in patients with recurrent high-grade glioma. Clin. Cancer Res. 17(20), 6562 (2011).
76. Xiangsong Z, Weian C. Differentiation of recurrent astrocytoma from radiation necrosis: a pilot study with 11N-NH3 PET. J. Neurooncol. 82(3), 305-311 (2007).
77. Schober O, Duden C, Meyer GJ, Müller JA, Hundeshagen H. Non selective transport of [11C-methyl]-l-and d-methionine into a malignant glioma. Eur. J. Nucl. Med. 13(2), 103-105 (1987).
78. Tsuyuguchi N, Takami T, Sunada I et al. Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery - in malignant glioma. Ann. Nucl. Med. 18(4), 291-296 (2004).
79. Terakawa Y, Tsuyuguchi N, Iwai Y et al. Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J. Nucl. Med. 49(5), 694-699 (2008).
80. Tripathi M, Sharma R, Varshney R et al. Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors. Clin. Nucl. Med. 37(2), 158-163 (2012).
81. Rachinger W, Goetz C, Pöpperl G et al. Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery, 505-511; discussion 505 (2005).
82. Mehrkens JH, Pöpperl G, Rachinger W et al. The positive predictive value of O-(2-[18F]fluoroethyl)-l-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment. J. Neurooncol. , 27-35 (2008).
83. Chen W, Silverman DH, Delaloye S et al. F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J. Nucl. Med. 47(6), 904-911 (2006).
84. Ledezma CJ, Chen W, Sai V et al. F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience. Eur. J. Radiol. 71(2), 242-248 (2009).
85. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 9(5), 453-461 (2008).
86. Giglio P, Gilbert MR. Cerebral radiation necrosis. Neurologist 9(4), 180-188 (2003).
87. Kumar AJ, Leeds NE, Fuller GN et al. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapyinduced necrosis of the brain after treatment. Radiology 217(2), 377-384 (2000).
88. Rusthoven KE, Olsen C, Franklin W et al. Favorable prognosis in patients with high-grade glioma with radiation necrosis: the University of Colorado reoperation series. Int. J. Radiat. Oncol. Biol. Phys. , 211-217 (2011).
89. Marks JE, Baglan RJ, Prassad SC, Blank WF. Cerebral radionecrosis: incidence and risk in relation to dose, time, fractionation and volume. Int. J. Radiat. Oncol. Biol. Phys. 7(2), 243-252 (1981).
90. Floyd NS, Woo SY, Teh BS et al. Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 58(3), 721-726 (2004).
91. Ruben JD, Dally M, Bailey M, Smith R, McLean CA, Fedele P. Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int. J. Radiat. Oncol. Biol. Phys. 65(2), 499-508 (2006).
92. DeAngelis LM. Brain tumors. N. Engl. J. Med. 344(2), 114-123 (2001).
93. Shaw E, Arusell R, Scheithauer B et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J. Clin. Oncol. , 2267-2276 (2002).